Neurizon Therapeutics (ASX:NUZ) submitted an investigational new drug application with the US Food and Drug Administration to conduct a phase 2/3 trial of its drug candidate, NUZ-001, for amyotrophic lateral sclerosis, according to a Wednesday filing with the Australian bourse.
Once approved, the Healey ALS Platform study will start patient enrollment in the first half of next year, the filing said.
Amyotrophic lateral sclerosis is a motor neuron disease characterized by the progressive degeneration of nerve cells in the spinal cord and brain, the Johns Hopkins Medicine website showed.
The company's shares were down 3% in recent Wednesday trade.
Price (AUD): $0.17, Change: $-0.01, Percent Change: -2.86%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.